ArticleBreast cancer (Tokyo, Japan)2024

Targeted therapies in HER2-positive breast cancer with receptor-redirected Arazyme-linker-Herceptin as a novel fusion protein.

Farideh Rahmani et al.PubMed ↗Publisher ↗

No numbers read from the abstract.